Target Name: WRAP53
NCBI ID: G55135
Review Report on WRAP53 Target / Biomarker Content of Review Report on WRAP53 Target / Biomarker
WRAP53
Other Name(s): WD repeat containing antisense to TP53, transcript variant 1 | WDR79 | WD40 repeat-containing protein encoding RNA antisense to p53 | WD40 protein Wrap53 | TCAB1_HUMAN | WD repeat containing antisense to TP53 | Telomerase Cajal body protein 1 | WD repeat-containing protein 79 | TCAB1 | WRAP53 variant 1 | WD40 repeat-containing protein antisense to TP53 | DKCB3 | WRAP53beta | WD Repeat Domain 79 | WRAP53 variant 2 | WD40 repeat-containing protein antisense to TP53 gene | WD repeat containing antisense to TP53, transcript variant 2 | FLJ10385 | WD repeat-containing protein WRAP53

WRAP53: A Potential Drug Target for Cancer

WRAP53, a gene that encodes a protein known as WRAP53, has been identified as a potential drug target or biomarker for various diseases, including cancer. The protein encoded by WRAP53 has unique properties that make it an attractive target for drug development due to its ability to interact with multiple signaling pathways and its critical role in various cellular processes.

WRAP53 is a key component of the transmembrane protein family, which includes proteins involved in intracellular signaling cascades. This family is known for its ability to regulate various cellular processes, including cell adhesion, migration, and invasion. WRAP53 is specifically involved in the regulation of cell growth and the response to external stimuli, making it a potential target for drugs that aim to modulate these processes.

One of the key features of WRAP53 is its ability to interact with multiple signaling pathways, including TP53 signaling. TP53 is a well-established gene that plays a critical role in the regulation of apoptosis, a critical mechanism by which cells respond to DNA damage and ensure proper cell growth and maintenance. The TP53 gene has four splice variants, each of which encodes a distinct protein with different properties. The most abundant variant, known as TP53 wild-type, is involved in the regulation of DNA damage repair, while the variant encoding the protein with the highest expression level, known as TP53 repeat containing antisense to TP53 (WRAP53), is involved in the regulation of apoptosis.

TheWRAP53 protein has been shown to play a critical role in the regulation of apoptosis, including the execution of programmed cell death. This is because WRAP53 is involved in the formation of a protein complex that spans the membrane of the cell and is composed of multiple subunits. This protein complex is known as the extrinsic apoptosis-associated protein 1 (AP-1) complex and is responsible for the execution of programmed cell death.

In addition to its involvement in apoptosis, WRAP53 has also been shown to play a critical role in the regulation of cell growth and the response to external stimuli. This is because the protein encoded by WRAP53 is involved in the regulation of various cellular processes, including cell adhesion, migration, and invasion. These properties make WRAP53 a potential target for drugs that aim to modulate these processes.

TheWRAP53 protein has also been shown to be involved in the regulation of cellular signaling pathways that are important for cancer progression. For example, studies have shown thatWRAP53 is involved in the regulation of theNotch signaling pathway, which is involved in the regulation of cell proliferation and survival. Additionally,WRAP53 is involved in the regulation of the TGF-β signaling pathway, which is involved in cell growth, differentiation, and survival.

In conclusion, WRAP53 is a gene that encodes a protein with unique properties that make it an attractive target for drug development. The protein encoded by WRAP53 has been shown to play a critical role in the regulation of various cellular processes, including apoptosis, cell growth, and signaling pathways. Its involvement in these processes makes it a potential drug target or biomarker for various diseases, including cancer. Further research is needed to fully understand the role of WRAP53 in these processes and to develop effective treatments for these diseases.

Protein Name: WD Repeat Containing Antisense To TP53

Functions: RNA chaperone that plays a key role in telomere maintenance and RNA localization to Cajal bodies (PubMed:29804836, PubMed:29695869). Specifically recognizes and binds the Cajal body box (CAB box) present in both small Cajal body RNAs (scaRNAs) and telomerase RNA template component (TERC) (PubMed:19285445, PubMed:20351177, PubMed:29804836, PubMed:29695869). Essential component of the telomerase holoenzyme complex, a ribonucleoprotein complex essential for the replication of chromosome termini that elongates telomeres in most eukaryotes (PubMed:19179534, PubMed:20351177, PubMed:26170453, PubMed:29695869). In the telomerase holoenzyme complex, required to stimulate the catalytic activity of the complex (PubMed:27525486, PubMed:29804836). Acts by specifically binding the CAB box of the TERC RNA and controlling the folding of the CR4/CR5 region of the TERC RNA, a critical step for telomerase activity (PubMed:29804836). In addition, also controls telomerase holoenzyme complex localization to Cajal body (PubMed:22547674). During S phase, required for delivery of TERC to telomeres during S phase and for telomerase activity (PubMed:29804836). In addition to its role in telomere maintenance, also required for Cajal body formation, probably by mediating localization of scaRNAs to Cajal bodies (PubMed:19285445, PubMed:21072240). Also plays a role in DNA repair: phosphorylated by ATM in response to DNA damage and relocalizes to sites of DNA double-strand breaks to promote the repair of DNA double-strand breaks (PubMed:25512560, PubMed:27715493). Acts by recruiting the ubiquitin ligase RNF8 to DNA breaks and promote both homologous recombination (HR) and non-homologous end joining (NHEJ) (PubMed:25512560, PubMed:27715493)

The "WRAP53 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about WRAP53 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

WRAP73 | WRN | WRNIP1 | WSB1 | WSB2 | WSCD1 | WSCD2 | WSPAR | WT1 | WT1-AS | WTAP | WTAPP1 | WTIP | WWC1 | WWC2 | WWC2-AS2 | WWC3 | WWOX | WWP1 | WWP2 | WWTR1 | WWTR1-AS1 | XAB2 | XACT | XAF1 | XAGE-4 | XAGE1A | XAGE1B | XAGE1D | XAGE2 | XAGE3 | XAGE5 | XBP1 | XCL1 | XCL2 | XCR1 | XDH | XG | XGY2 | XIAP | XIRP1 | XIRP2 | XIST | XK | XKR3 | XKR4 | XKR5 | XKR6 | XKR7 | XKR8 | XKR9 | XKRX | XKRY | XKRYP7 | XLOC_007697 | XLOC_008559 | XLOC_009911 | XNDC1N | XPA | XPC | XPC complex | XPNPEP1 | XPNPEP2 | XPNPEP3 | XPO1 | XPO4 | XPO5 | XPO6 | XPO7 | XPOT | XPR1 | XRCC1 | XRCC2 | XRCC3 | XRCC4 | XRCC5 | XRCC6 | XRCC6P5 | XRN1 | XRN2 | XRRA1 | XXYLT1 | XXYLT1-AS2 | XYLB | XYLT1 | XYLT2 | YAE1 | YAF2 | YAP1 | YARS1 | YARS2 | YBEY | YBX1 | YBX1P1 | YBX1P10 | YBX1P2 | YBX1P4 | YBX2 | YBX3 | YBX3P1